Report cover image

Global Myocardial Infarction Therapeutics Market Size Study, by Therapeutic Class (Antiplatelet Agents, Antithrombotic Agents, Nitrates, Calcium Channel Blockers, Lipid-Lowering Agents), by Route of Administration (Oral, Intravenous, Subcutaneous, Transde

Publisher Factview Research
Published Jul 03, 2025
Length 285 Pages
SKU # FAVR20379099

Description

The Global Myocardial Infarction Therapeutics Market is estimated to be valued at USD 16.18 billion in 2024 and is projected to grow at a CAGR of 4.3% over the forecast period 2024-2034. Myocardial infarction therapeutics encompass a range of treatments aimed at managing and mitigating the effects of a heart attack. These include acute interventions such as thrombolytic therapy, which dissolves blood clots obstructing coronary arteries, and percutaneous coronary interventions (PCI), such as angioplasty and stent placement to restore blood flow. Medications play a crucial role, including antiplatelet agents, anticoagulants, and beta-blockers, which reduce the heart's workload and prevent further clot formation. Long-term management may involve lifestyle modifications, statins to manage cholesterol levels, and medications to control blood pressure. Collectively, these strategies aim to restore heart function, prevent complications, and improve overall prognosis. Furthermore, advances in pharmacology are leading to the development of novel drugs, including new anticoagulants, antiplatelet agents, and drugs targeting specific pathways involved in myocardial infarction. These innovations aim to improve efficacy and reduce side effects.

The substantial growth can be attributed to the increasing prevalence of cardiovascular diseases (CVDs), which have been the leading cause of death globally for the past 15 years. Factors such as sedentary lifestyles, unhealthy diets, tobacco use, and an aging population further contribute to the rising incidence of myocardial infarction, driving the demand for effective therapeutic solutions. Technological advancements in treatment modalities are another significant driver of market growth. Continuous innovation in drug development, including the introduction of novel therapies such as gene therapy, stem cell therapy, and personalized medicine approaches, is expected to enhance treatment outcomes and reduce mortality rates. The adoption of telemedicine and remote patient monitoring also facilitates better access to healthcare services, especially in underserved regions, thus expanding the market reach.

The key region in the Global Myocardial Infarction Therapeutics Market includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2024, North America dominates the market in terms of revenue, supported by a well-established healthcare infrastructure, high prevalence of cardiovascular diseases, and robust research and development activities. The region benefits from cutting-edge treatments, including innovative drugs and advanced medical technologies, alongside a strong emphasis on healthcare access and patient management, driving its leading market position. Europe follows closely, driven by an increasing geriatric population and rising healthcare expenditure. The Asia-Pacific region expected to grow at fastest growth rate during the forecast period 2024-2034, due to heightened awareness about cardiovascular health, improving healthcare systems, and rising disposable incomes.

Major market players included in this report are:

Bayer AG

Eli Lilly and Company

Johnson & Johnson

Bristol-Myers Squibb Company

Boehringer Ingelheim International GmbH

Merck & Co., Inc.

Teva Pharmaceutical Industries Ltd.

Abbott Laboratories

Novartis AG

Sanofi Aventis US, LLC

AstraZeneca plc

Pfizer Inc.

Roche Holding AG

The detailed segments and sub-segment of the market are explained below:

By Therapeutic Class:

Antiplatelet Agents

Antithrombotic Agents

Nitrates

Calcium Channel Blockers

Lipid-Lowering Agents

By Route of Administration:

Oral

Intravenous

Subcutaneous

Transdermal

By Indication:

ST-Elevation Myocardial Infarction (STEMI)

Non-ST-Elevation Myocardial Infarction (NSTEMI)

Unstable Angina

By Mechanism of Action:

Platelet Aggregation Inhibitors (P2Y12 Inhibitors, GPIIb/IIIa Inhibitors)

Thrombin Inhibitors

Anticoagulants

Calcium Channel Blockers

HMG-CoA Reductase Inhibitors

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2024

Forecast period – 2024 to 2034

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2034.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Table of Contents

285 Pages
Chapter 1. Global Myocardial Infarction Therapeutics Market Executive Summary
1.1. Global Myocardial Infarction Therapeutics Market Size & Forecast (2024-2034)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Therapeutic Class
1.3.2. By Route of Administration
1.3.3. By Indication
1.3.4. By Mechanism of Action
1.4. Key Trends
1.5. Recession Impact
1.6 Investment Analysis
1.7 Investment Rationale
1.8 Key Industry Metrics
1.9. Analyst Recommendation & Conclusion
Chapter 2. Global Myocardial Infarction Therapeutics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Myocardial Infarction Therapeutics Market Dynamics
3.1. Market Drivers
3.1.1. Rising Prevalence of Cardiovascular Diseases
3.1.2. Technological Advancements in MI Treatment
3.1.3. Increasing Healthcare Expenditure
3.2. Market Challenges
3.2.1. High Cost of Treatment
3.2.2. Limited Accessibility in Developing Regions
3.3. Market Opportunities
3.3.1. Development of Novel Treatments
3.3.2. Adoption of Telemedicine and Remote Patient Monitoring
3.3.3. Shift Towards Minimally Invasive Procedures
Chapter 4. Global Myocardial Infarction Therapeutics Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Therapeutic Class 2024-2034
5.1. Segment Dashboard
5.2. Global Myocardial Infarction Therapeutics Market: Therapeutic Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Antiplatelet Agents
5.2.2. Antithrombotic Agents
5.2.3. Nitrates
5.2.4. Calcium Channel Blockers
5.2.5. Lipid-Lowering Agents
Chapter 6. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Route of Administration 2024-2034
6.1. Segment Dashboard
6.2. Global Myocardial Infarction Therapeutics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Oral
6.2.2. Intravenous
6.2.3. Subcutaneous
6.2.4. Transdermal
Chapter 7. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Indication 2024-2034
7.1. Segment Dashboard
7.2. Global Myocardial Infarction Therapeutics Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. ST-Elevation Myocardial Infarction (STEMI)
7.2.2. Non-ST-Elevation Myocardial Infarction (NSTEMI)
7.2.3. Unstable Angina
Chapter 8. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Mechanism of Action 2024-2034
8.1. Segment Dashboard
8.2. Global Myocardial Infarction Therapeutics Market: Mechanism of Action Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Platelet Aggregation Inhibitors (P2Y12 Inhibitors, GPIIb/IIIa Inhibitors)
8.2.2. Thrombin Inhibitors
8.2.3. Anticoagulants
8.2.4. Calcium Channel Blockers
8.2.5. HMG-CoA Reductase Inhibitors
Chapter 9. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Region 2024-2034
9.1. North America Myocardial Infarction Therapeutics Market
9.1.1. U.S. Myocardial Infarction Therapeutics Market
9.1.1.1. Therapeutic Class Breakdown Size & Forecasts, 2024-2034
9.1.1.2. Route of Administration Breakdown Size & Forecasts, 2024-2034
9.1.1.3. Indication Breakdown Size & Forecasts, 2024-2034
9.1.1.4. Mechanism of Action Breakdown Size & Forecasts, 2024-2034
9.1.2. Canada Myocardial Infarction Therapeutics Market
9.2. Europe Myocardial Infarction Therapeutics Market
9.2.1. U.K. Myocardial Infarction Therapeutics Market
9.2.2. Germany Myocardial Infarction Therapeutics Market
9.2.3. France Myocardial Infarction Therapeutics Market
9.2.4. Spain Myocardial Infarction Therapeutics Market
9.2.5. Italy Myocardial Infarction Therapeutics Market
9.2.6. Rest of Europe Myocardial Infarction Therapeutics Market
9.3. Asia-Pacific Myocardial Infarction Therapeutics Market
9.3.1. China Myocardial Infarction Therapeutics Market
9.3.2. India Myocardial Infarction Therapeutics Market
9.3.3. Japan Myocardial Infarction Therapeutics Market
9.3.4. Australia Myocardial Infarction Therapeutics Market
9.3.5. South Korea Myocardial Infarction Therapeutics Market
9.3.6. Rest of Asia Pacific Myocardial Infarction Therapeutics Market
9.4. Latin America Myocardial Infarction Therapeutics Market
9.4.1. Brazil Myocardial Infarction Therapeutics Market
9.4.2. Mexico Myocardial Infarction Therapeutics Market
9.4.3. Rest of Latin America Myocardial Infarction Therapeutics Market
9.5. Middle East & Africa Myocardial Infarction Therapeutics Market
9.5.1. Saudi Arabia Myocardial Infarction Therapeutics Market
9.5.2. South Africa Myocardial Infarction Therapeutics Market
9.5.3. Rest of Middle East & Africa Myocardial Infarction Therapeutics Market
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Company 1
10.1.2. Company 2
10.1.3. Company 3
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Bristol-Myers Squibb Company
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Boehringer Ingelheim International GmbH
10.3.3. Merck & Co., Inc.
10.3.4. Teva Pharmaceutical Industries Ltd.
10.3.5. Abbott Laboratories
10.3.6. Novartis AG
10.3.7. Sanofi Aventis US, LLC
10.3.8. AstraZeneca plc
10.3.9. Pfizer Inc.
10.3.10. Roche Holding AG
10.3.11. Bayer AG
10.3.12. Eli Lilly and Company
10.3.13. Johnson & Johnson
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us